ctDNA Test Is Predictive of Adjuvant Atezolizumab Benefit in MIBC

IMvigor011 Confirms ctDNA-Guided Care in Bladder Cancer

IMvigor011 showed significant improvement in survival outcomes with adjuvant atezolizumab in ctDNA-positive MIBC.

Bladder Cancer Adjuvant Immunotherapy Benefit Predicted by Signatera Test

Topline results from new trial results show that Signatera-positive patients treated with Roche’s atezolizumab (Tecentriq) had statistically significant and clinically meaningful improvements in disease-free and overall survival. Signatera is Natera’s ctDNA test. Tecentriq is a cancer immunotherapy. “The results of IMvigor011 are very significant, opening the door for a new treatment paradigm for bladder cancer patients who are positive for recu…

ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC

Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.

Natera pursues ctDNA assay approval after Phase III victory

Natera's ctDNA assay Signatera improved survival outcomes for patients with MRD-positive muscle-invasive bladder cancer (MIBC).The post Natera pursues ctDNA assay approval after Phase III victory  appeared first on Clinical Trials Arena.

Landmark IMvigor011 Trial Validates ctDNA-Guided MIBC Therapy

New research reveals how ctDNA testing transforms treatment for muscle-invasive bladder cancer, identifying patients who benefit from targeted immunotherapy.

IMvigor011: ctDNA test can predict adjuvant immunotherapy benefit in MIBC

Patients who were Signatera positive and received treatment with atezolizumab had a statistically significant and clinically meaningful improvement in DFS and OS.